Market closed
Silverback Therapeutics/$SPRY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Silverback Therapeutics
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Ticker
$SPRY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
26
Website
SPRY Metrics
BasicAdvanced
$1.6B
Market cap
-
P/E ratio
-$0.47
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$1.6B
52-week high
$16.54
52-week low
$3.38
Average daily volume
886K
Financial strength
Current ratio
32.823
Quick ratio
32.527
Total debt to equity
0.074
Management effectiveness
Return on assets (TTM)
-14.75%
Return on equity (TTM)
-19.34%
Valuation
Price to revenue (TTM)
3,107.432
Price to book
7.27
Price to tangible book (TTM)
7.27
Price to free cash flow (TTM)
-35.126
Growth
Revenue change (TTM)
128.31%
Earnings per share change (TTM)
-37.12%
What the Analysts think about SPRY
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Silverback Therapeutics stock.
SPRY Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SPRY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SPRY News
AllArticlesVideos
ARS Pharmaceuticals, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
Accesswire·4 days ago
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
Accesswire·5 days ago
ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Silverback Therapeutics stock?
Silverback Therapeutics (SPRY) has a market cap of $1.6B as of November 09, 2024.
What is the P/E ratio for Silverback Therapeutics stock?
The price to earnings (P/E) ratio for Silverback Therapeutics (SPRY) stock is 0 as of November 09, 2024.
Does Silverback Therapeutics stock pay dividends?
No, Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders as of November 09, 2024.
When is the next Silverback Therapeutics dividend payment date?
Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders.
What is the beta indicator for Silverback Therapeutics?
Silverback Therapeutics (SPRY) does not currently have a Beta indicator.